NCT06310382View on ClinicalTrials.gov

GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

May 26, 2025

Study Completion Date

August 4, 2025

Conditions
Advanced Solid Tumors With MAPK Signal Pathway Mutations
Interventions
DRUG

GH55

GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.

Trial Locations (1)

200120

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

collaborator

Shandong Tumor Hospital

OTHER

lead

Suzhou Genhouse Bio Co., Ltd.

OTHER